Agios Pharmaceuticals

Agios blood cancer drug lead jumps ship to Aprea Therapeutics
Agios blood cancer drug lead jumps ship to Aprea Therapeutics
Fierce Biotech
Aprea
Agios Pharmaceuticals
Flag link:
Smaller groups await Bristol-Myers Squelgene fallout
Smaller groups await Bristol-Myers Squelgene fallout
EP Vantage
M&A
Bristol-Myers Squibb
Celgene
Vividion Therapeutics
Evotec
Prothena
Anokion
Skyhawk Therapeutics
Dragonfly Therapeutics
BeiGene
Agios Pharmaceuticals
Jounce Therapeutics
Flag link:
Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More
Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More
Xconomy
Celgene
M&A
Juno Therapeutics
Kite Therapeutics
Bluebird Bio
Agios Pharmaceuticals
Jounce Therapeutics
BieGene
Acceleron
Flag link:
Could These Be the Next 2 Biotech Buyouts?
Could These Be the Next 2 Biotech Buyouts?
Motley Fool
biotech
M&A
Agios Pharmaceuticals
Clovis Oncology
Flag link:
Ready to Roll! Ten Q3 Biotech Earnings Reports to Watch Next Week
Ready to Roll! Ten Q3 Biotech Earnings Reports to Watch Next Week
BioSpace
BrainStorm Cell Therapeutics
Allergan
Pfizer
Clovis Oncology
Acorda Therapeutics
Takeda
Agios Pharmaceuticals
Shire
Teva Pharmaceutical
AbbVie
Flag link:
Agios Pharma names a new CEO, one with commercial chops in biotech
Agios Pharma names a new CEO, one with commercial chops in biotech
Stat
Pharma CEOs
Jackie Fouse
Agios Pharmaceuticals
Flag link:
Agios scores its second new drug approval, ivosidenib heads to the AML market
Agios scores its second new drug approval, ivosidenib heads to the AML market
Endpoints
Agios Pharmaceuticals
ivosidenib (AG-120)
AML
acute myeloid leukemia
Flag link:
Celgene on biotech hunt with Agios, Jounce in crosshairs: FT
Celgene on biotech hunt with Agios, Jounce in crosshairs: FT
Fierce Biotech
Celgene
M&A
Agios Pharmaceuticals
Jounce Therapeutics
Flag link:
Agios spotlights promising data for IDH1 drug, putting it on the path to FDA submission
Agios spotlights promising data for IDH1 drug, putting it on the path to FDA submission
Endpoints
Agios Pharmaceuticals
ASH
FDA
IDH1
ivosidenib
Flag link:
Agios Pharma shares dive after anemia treatment development halted
Agios Pharma shares dive after anemia treatment development halted
Marketwatch
Agios Pharmaceuticals
clinical trials
AG-519
pyruvate kinase deficiency
Flag link:
3 Drugs Heading to the FDA Soon
3 Drugs Heading to the FDA Soon
Motley Fool
FDA
Kite Pharma
KTE-C19
Flexion
Zilretta
AG-221
Agios Pharmaceuticals
Celgene
Flag link:
5 Major Clinical Trial Results Coming Up
5 Major Clinical Trial Results Coming Up
24/7 Wall St
clinical trials
Vertex Pharmaceuticals
Orkambi
Puma Biotechnology
neratinib
GW Pharma
Epidiolex
Agios Pharmaceuticals
AG-348
AG-519
Dermira
DRM-04
Flag link:
Celgene expands partnership with Agios into immuno-oncology
Celgene expands partnership with Agios into immuno-oncology
BioPharma Dive
Celgene
Agios Pharmaceuticals
immuno-oncology
AG-120
Flag link:
Who Is Gilead Going To Buy?
Who Is Gilead Going To Buy?
Seeking Alpha
Gilead Sciences
M&A
Genfit
Intercept Pharma
Agios Pharmaceuticals
Ziopharm
Flag link:
Agios Pharma Plunges 15% Despite Strong Data for Leukemia Drug
Agios Pharma Plunges 15% Despite Strong Data for Leukemia Drug
Barron's
Agios Pharmaceuticals
AG-221
leukemia
Flag link:
Celgene's 3 Most Important Collaborations
Celgene's 3 Most Important Collaborations
Investopedia
Celgene
Agios Pharmaceuticals
OncoMed
MedImmune
Flag link:
A pair of Celgene partners gets on the FDA fast track
A pair of Celgene partners gets on the FDA fast track
Fierce Biotech
Celgene
FDA
fast track
luspatercept
Acceleron
beta-thalassemia
AG-120
Agios Pharmaceuticals
Flag link:
Agios Pharmaceuticals reports 4Q loss
Agios Pharmaceuticals reports 4Q loss
Yahoo/AP
Agios Pharmaceuticals
earnings
Flag link:
The Best Performing Biotech Stocks of 2014: Amazing 300% Gainers
The Best Performing Biotech Stocks of 2014: Amazing 300% Gainers
24/7 Wall St
Agios Pharmaceuticals
OvaScience
Radius
Prosensa
TG Therapeutics
Bluebird Bio
Receptos
Flag link:
Best and worst 2014 biotech performers on Wall Street
Best and worst 2014 biotech performers on Wall Street
Fierce Biotech
Avanir Pharmaceuticals
Agios Pharmaceuticals
TG Therapeutics
Bluebird Bio
Vivus
Agerion
Theravance
Flag link:

Pages